Can you take Belantamab mafodotin with Quadramet?
1 drug interaction and 2 additional warnings found for the following 2 drugs:
- belantamab mafodotin
- Quadramet (samarium sm 153 lexidronam)
Drug interactions
Major drug interactions
Major:
samarium sm 153 lexidronam belantamab mafodotin
Applies to: Quadramet (samarium sm 153 lexidronam) and belantamab mafodotin
Using samarium sm 153 lexidronam together with belantamab mafodotin may increase the risk of side effects that affect your bone marrow function, resulting in low numbers of different types of blood cells. You may be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. You should seek medical attention if you develop paleness, fatigue, dizziness, fainting, unusual bruising or bleeding, fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Disease interactions
2 potential interactions Applies to: 2 conditions, including Liver Disease and Visual Defect/Disturbance.
Liver Disease
Moderate:
belantamab mafodotin
Belantamab mafodotin has a moderate potential interaction with Liver Disease.
Belantamab has not been studied in patients with moderate or severe hepatic impairment. No dosage modification is required in patients with mild hepatic impairment.
Visual Defect/Disturbance
Major:
belantamab mafodotin
Belantamab mafodotin has a major potential interaction with Visual Defect/Disturbance.
Belantamab has caused ocular toxicity resulting in changes in vision, including severe vision loss and corneal ulcer, and symptoms such as blurred vision and dry eyes. Ophthalmic exams should be performed at baseline, prior to each dose, and promptly for new or worsening symptoms. Due to the risk of ocular toxicity, this drug is only available through a restricted program under the Risk Evaluation and Mitigation Strategy (REMS).
Report options
More resources
belantamab mafodotin
A total of 211 drugs are known to interact with belantamab mafodotin.
- Belantamab mafodotin is in the drug class miscellaneous antineoplastics.
- Belantamab mafodotin is used to treat Multiple Myeloma.
Quadramet
A total of 223 drugs are known to interact with Quadramet.
- Quadramet is in the drug class therapeutic radiopharmaceuticals.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.